Voyager Acquisition Corp./Cayman Islands — fact timeline

Voyager Acquisition Corp./Cayman Islands entered into Purchase Agreement with investors listed on the Schedule of Buyers valued at $27,500,000 (effective 2026-05-27).

“On May 27, 2026, Voyager Acquisition Corp., a Cayman Islands exempted company with limited liability (“Voyager”), Veraxa Biotech AG, a public limited company organized under the laws of Switzerland (the “Company”), and Veraxa Biotech Holding AG, a company limited by shares organized under the laws of Switzerland (“PubCo”), entered into a securities purchase agreement (the “Purchase Agreement”) with each of the investors listed on the Schedule of Buyers attached thereto (each, a “Buyer” and collectively, the “Buyers”), pursuant to which PubCo agreed to issue and sell, in a private placement exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder (the “Private Placement”): (i) senior secured notes of PubCo due August 27, 2027 (the “Notes”) in an aggregate principal amount of $27,500,000, and (ii) warrants (the “Warrants” and, together with the Notes, the “Securities”) to purchase up to 2,391,305”

Voyager Acquisition Corp./Cayman Islands incurred senior notes of $27,500,000 with the investors listed on the Schedule of Buyers attached thereto at Notes bear interest at a rate of 15% per annum upon default maturing August 27, 2027.

“PubCo will issue Notes in an aggregate principal amount of $27,500,000. The Notes mature fifteen (15) months from the date of issuance.”

Voyager Acquisition Corp./Cayman Islands amended First Amendment to Sponsor Support Agreement with Veraxa and Voyager Acquisition Sponsor Holdco LLC (effective 2026-02-02).

“On February 2, 2026, Veraxa and Voyager Acquisition Sponsor Holdco LLC (the “ Sponsor ”) entered into that certain First Amendment to Sponsor Support Agreement, amending that certain Sponsor Support Agreement dated as of April 22, 2025 (the “ Sponsor Support Agreement ”), between the Company, Veraxa and the Sponsor, pursuant to which the Sponsor agreed, in connection with the Closing (as defined in the BCA), to forfeit for cancellation for no consideration 200,000 Class B Ordinary Shares (as defined in the BCA) and 400,000 SPAC Warrants (as defined in the BCA) for which a corresponding number of PubCo Ordinary Shares (as defined therein) and PubCo Warrants (as defined in the BCA) will be issued to shareholders of Veraxa.”

Voyager Acquisition Corp./Cayman Islands amended Second Amendment and Waiver with Veraxa Biotech AG and Oliver Baumann valued at $1,350,000,000 (effective 2026-02-02).

“On February 2, 2026, Voyager Acquisition Corp. (the “ Company ”) entered into that certain Second Amendment and Waiver (the “ Amendment ”) to that certain Business Combination Agreement dated as of April 22, 2025 as amended on October 18, 2025 (the “ BCA ”), by and among the Company, Veraxa Biotech AG (“ Veraxa ”), and Oliver Baumann, in his capacity as representative for the shareholders of Veraxa.”